BOSTON (Thomson Financial) - OMRIX Biopharmaceuticals Inc. Monday said its
has received approval from the Food and Drug Administration to begin a Phase II
clinical trial in the U.S. for its Fibrin Patch in mild to moderate bleeding.
The company expects the trial to begin in the second quarter of 2008.
Shares of the New York-based provider of biosurgical and immunotherapy
products closed Friday at $13.87.
Casey Logan
cl/vj
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|